European Medicines Agency’s data protection notice for PMS user acceptance stakeholder involvement

Human medicines European public assessment report (EPAR): Pedea, ibuprofen, Date of authorisation: 28/07/2004, Revision: 18, Status: Authorised

Accessibility

Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Sirturo, bedaquiline, Date of authorisation: 05/03/2014, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Lupkynis, voclosporin, Date of authorisation: 15/09/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Opdualag, relatlimab,nivolumab, Date of authorisation: 15/09/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Reblozyl, luspatercept, Date of authorisation: 25/06/2020, Revision: 10, Status: Authorised

Agenda of the PRAC meeting 24 - 27 November 2025

Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 16, Status: Authorised